Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 3/20 | 0.42 |
| ▸ | CPB1 | P15086 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137705 | 0.92 | CTSB (0.41) | RAB9ACTSBCTSSCTSKCASP3 | |
| SCHEMBL12993235 | 0.92 | CTSB (0.41) | RAB9ACTSBCTSSCTSKCASP3 | |
| SCHEMBL12993249 | 0.89 | CTSB (0.39) | RAB9ACTSBCTSSCTSKCASP3 | |
| SCHEMBL12993327 | 0.89 | CTSB (0.39) | RAB9ACTSBCTSSCTSKCASP3 | |
| SCHEMBL12993332 | 0.89 | CTSB (0.39) | RAB9ACTSBCTSSCTSKCASP3 | |
| SCHEMBL12993074 | 0.87 | CTSB (0.39) | RAB9ACTSBCTSSCTSKCASP3 | |
| SCHEMBL10137708 | 0.87 | CTSB (0.42) | RAB9ACTSBCTSSCTSKCASP3 | |
| SCHEMBL12993240 | 0.84 | RAB9A (0.44) | RAB9ACTSBCTSSCTSKCASP3 | |
| SCHEMBL7138791 | 0.83 | RAB9A (0.50) | RAB9AKMT2ARORC | |
| SCHEMBL10169343 | 0.78 | ADAM17 (0.39) | CTSBCTSSCTSKCASP3CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2012-01-26 | — | — | US | disclosed |
| US-7858737-B2 | Heterogeneous foldamers containing α, β, and/or γ-amino acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | DNPEP, PRKCSH, YWHAZ | RAB9A 3084/4885CTSB 1184/4885CTSS 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.